Study of avapritinib for indolent systemic mastocytosis
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This study looks at how avapritinib works in people with indolent systemic mastocytosis whose symptoms are not well controlled by other treatments. You will take the drug as part of your usual care, and researchers will collect information to see how well it helps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with indolent systemic mastocytosis.
- Your symptoms are moderate to severe and not well controlled by other treatments.
- Your doctor has decided to start you on avapritinib as part of your regular care.
- You have not had a bleeding event in the past year, such as a stroke or brain bleed.
- You have never taken avapritinib before, either in a study or as a prescribed drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is observing adults with indolent systemic mastocytosis (ISM) who are already receiving or planning to start symptom treatments or the drug avapritinib. It aims to learn more about how these treatments work in real life.
This trial tests BLU-263, a study medicine, against placebo (inactive treatment) to see if it improves symptoms in people with indolent systemic mastocytosis. It also checks safety and how well the dose is tolerated before and during treatment.
This study looks at a personalized approach to managing indolent systemic mastocytosis, a condition where too many mast cells build up in the body. The goal is to see if tailoring treatment based on individual characteristics can improve symptoms and quality of life.
This trial tests a combination of two drugs, avapritinib and decitabine, for people with systemic mastocytosis plus another blood cancer (SM-AHN). The goal is to see if the combination works better than either drug alone.
This study provides continued access to avapritinib for people who have already been in a Blueprint Medicines trial and are still benefiting from the drug. It allows you to keep receiving treatment while staying monitored for safety.
This study looks at how well avapritinib works and how safe it is for people with metastatic or unresectable gastrointestinal stromal tumors (GIST). It focuses on whether the tumor has certain marker and gene features and whether you can tolerate related medications.
Hear when a new Indolent Systemic Mastocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.